August 02, 2018
TCS named a leader in Life Sciences Digital Services in North America by Everest Group
Tata Consultancy Services’ Business 4.0 thought leadership framework, digital transformational capabilities and consistency of performance cited as key strengths
NEW YORK | MUMBAI: Tata Consultancy Services (TCS), (BSE: 532540, NSE: TCS), a leading global IT services, consulting and business solutions organisation, has been named a leader in Everest Group’s Services PEAK Matrix™ 2018 for Life Sciences Digital Services in North America.1
The PEAK Matrix™ positioned TCS the highest for market impact, listing its digital transformation capabilities, consistency of performance and next-generation digital solutions – such as the Advanced Drug Development Platform that uses artificial intelligence and IoT for drug development and patient engagement – as key strengths.
Debashis Ghosh, president, life sciences and healthcare, TCS, said, “Life sciences companies are accelerating their digital transformation journeys in pursuit of their growth agenda, embracing AI for drug discovery and development, cloud for data management, and automation and IoT for connected health. Our leader position is a validation of our vision and ability to leverage the Business 4.0 thought leadership framework for those transformation journeys and the resultant market success that we are seeing.”
TCS partners with leading life sciences companies in leveraging next generation platforms and emerging technologies to drive innovation, gain speed-to-market and drive internal efficiencies. The company offers a full set of digital transformation services and solutions including consulting, predictive and prescriptive analytics, genomics research, advanced platform solutions and cognitive business operations. Early investments in building capabilities in digital technologies in the form of reskilling the workforce, agile workplaces and intellectual property have helped TCS gain significant scale and depth in the digital space.
TCS’ experts in the life sciences domain work closely with solution architects to come up with innovative solutions that use a combination of user-friendly omnichannel front-end technologies, IoT, big data analytics, cognitive computing capabilities, robotic process automation and cloud to reimagine the life sciences value chain. The company’s extensive portfolio of intellectual property – such as the Advanced Drug Development platform, Decision Fabric™ for drug safety and pharma, Connected Universe Platform and Customer Engagement Platform – help customers achieve better speed to market and superior business outcomes.
Jimit Arora, partner, Everest Group, said, “North American life sciences enterprises are getting serious about digital transformation. A mix of market changes and demand dynamics – including the need for faster time to market, acceleration of personalised medicine, movement towards value-based care, evolving patient expectations, and the boost from US tax reform – is driving the change. TCS, with its focus on next-generation digital solutions, such as ADD leveraging AI and IoT for drug development and patient engagement, is emerging as a credible digital transformation partner. With its Business 4.0 framework, TCS is able to position itself as a thought leader to help life sciences clients contextualise the disruptive impact of technology to transform their business."
Mr Ghosh added, “Our Life Sciences domain expertise, contextual knowledge, scale and depth of digital capabilities, investments in intellectual property and focus on the pillars of digital transformation, make us the preferred partner for life sciences customers in their Business 4.0 journeys.”
Read TCS' profile in Everest Group's Life Sciences Digital Services for North America Peak Matrix Report.
1 Life Sciences Digital Services in North America – Service Provider Landscape with Services Peak MatrixTM Assessment 2018, Everest Group, June 2018